GlassScriptPhysician profile
Jeffrey Wayne Singley
NPI 1457323305
$2,815.43
in general payments reported to CMS, 2019-2025
27 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $56.97 · 2024: $1,265 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,815.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.89 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $296.13 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $223.76 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $199.36 | 2024-2025 | Veozah |
| Novo Nordisk INC | $187.89 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $173.29 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $157.73 | 2024-2025 | |
| Pfizer INC. | $145.97 | 2024-2025 | |
| Lundbeck LLC | $142.02 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $98.53 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $97.49 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $87.43 | 2024-2025 | Verquvo, Lagevrio |
| Boston Scientific Corporation | $72.17 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.31 | 2024-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.93 | 2025 | Caplyta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $46.93 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $43.03 | 2025 | Trelegy Ellipta, Arexvy |
| Vanda Pharmaceuticals INC. | $38.89 | 2025 | Fanapt, Hetlioz |
| Amneal Pharmaceuticals LLC | $28.77 | 2024 | Unithroid |
| Heartflow, INC. | $25.87 | 2024 | |
| Sumitomo Pharma America, INC. | $22.58 | 2024 | Gemtesa |
| Neurocrine Biosciences, INC. | $20.42 | 2025 | |
| Abbott Laboratories | $19.89 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $16.64 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $13.85 | 2024 | Eliquis |
| Amgen INC. | $13.76 | 2025 | Repatha, Otezla |
| Tms Neurohealth Centers INC. | $12.90 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Singley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.